View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
August 12, 2021updated 11 Jul 2022 9:50am

Increased use of virtual trials has contributed to improved trial accrual rates

Researchers have attributed a rise in trial recruitment to the increased use of virtual trials and mobile data collection devices.

By GlobalData Healthcare

The current, traditional clinical trial model is outdated and is causing issues for patients, trial sites and sponsors. These issues include low recruitment and retention rates, leading to trial delays and increased costs for sponsors. Recruitment and retention or accrual issues are normally due to the distance from a patient’s home to a trial site, the number of visits required, complex trial protocols, lack of patient support, and little or no reimbursement of expenses. Virtual clinical trials use digital technologies and other processes that differ from traditional trial models to bring research closer to patients’ homes and improve their experience by reducing or even eliminating the number of physical site visits required.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Examples of digital technologies used in virtual trials include e-consent, telemedicine, electronic clinical outcome assessment (eCOA), remote patient monitoring (RPM) and wearables. Other processes include direct-to-patient (DtP) shipping of drugs and other supplies to a patient’s home, as well as in-home care with mobile nurses.

According to GlobalData’s Clinical Trials Database, almost 14,000 clinical trials were suspended, terminated or withdrawn between 2011 and July 2021. The main reason given for these trials ending was low accrual rates, as seen in 3,923 trials (28%). This is followed by other reasons (27% of trials) and unspecified reasons (23%), while a lack of efficacy was cited as the reason for 7% of these trials. Looking specifically at the proportion of trials by end date that were stopped or suspended due to low accrual rates compared to all stopped or suspended trials, the percentage has decreased somewhat over the past ten years, from 32% in 2011 to 19% in 2020 (Figure 1).

Data from GlobalData’s Clinical Trial Database also show that the proportion of clinical trials using virtual components has increased from 1.3% of all trials in 2011 to 3.5% of all trials this year to date. When these two datasets are combined, the decrease in issues that can cause low accrual rates could be attributed to the increased use of virtual trial components (Figure 1). These results correlate with the results of a 2020 study by the Tufts Centre for the Study of Drug Development, which found that recruitment rates for trials improved between 2012 (47%) and 2019 (77%). Study researchers attributed this improvement to increased use of virtual trials and mobile data collection devices, as well as more involvement of patients in protocol development.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology